A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
CONCLUSIONS: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population.
PMID: 31230047 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E Tags: Oncology Source Type: research
More News: Adenocarcinoma | Anemia | Breast Cancer | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Pneumonia | Study | USA Health